Invivyd Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Jeremy Gowler

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.1yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

CEO

Jeremy Gowler (46 yo)

no data

Tenure

Mr. Jeremy Gowler is Interim Chief Executive Officer of Invivyd, Inc. from April 11, 2024. Mr. Gowler served as Chief Operating Officer & Chief Commercial Officer of Invivyd, Inc. from December 16, 2022 un...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jill Andersen	Chief Legal Officer & Corporate Secretary	2.4yrs	US$3.86m	0.0023% $ 5.9k
Jeremy Gowler	Interim Chief Executive Officer	no data	no data	no data
William Duke	Chief Financial Officer	less than a year	no data	no data
Stacy Price	Chief Technology & Manufacturing Officer	1.1yrs	no data	no data
Robert Allen	Chief Scientific Officer	less than a year	no data	no data
Scott Young	Senior Vice President of Investor Relations & Corporate Communications	no data	no data	no data
Julie Green	Chief Human Resources Officer	1.3yrs	no data	no data
Heidi Spurling	VP of Strategy & Operations and Chief of Staff to the CEO	1.3yrs	no data	no data

1.1yrs

Average Tenure

50.5yo

Average Age

Experienced Management: IVVD's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Terrance McGuire	Director	3.5yrs	US$201.22k	0% $ 0
Michael Wyzga	Independent Director	2.8yrs	US$225.09k	0% $ 0
Clive Meanwell	Director	1.8yrs	US$336.78k	0.44% $ 1.1m
Marc Elia	Independent Chairperson of the Board	1.8yrs	US$352.99k	no data
Tomas Heyman	Independent Director	2.8yrs	US$220.36k	0% $ 0
Christine Lindenboom	Independent Director	1.5yrs	US$356.54k	no data
Tamsin Berry	Director	1.8yrs	US$334.50k	no data
Sara Cotter	Director	less than a year	no data	0.00084% $ 2.2k

1.8yrs

Average Tenure

65yo

Average Age

Experienced Board: IVVD's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Invivyd Management

Management criteria checks 0/4

Key information

Recent management updates

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

Invivyd, Inc. Announces Executive Changes

Recent updates

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

No longer forecast to breakeven

Mithril Capital Provides Information to Shareholders of Adagio Therapeutics

Adagio Therapeutics, Inc. Provides Update on Timing of Adintrevimab EUA Request

No longer forecast to breakeven

No longer forecast to breakeven

Mithril Capital Management Communicates with Adagio Therapeutics

Adagio Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2022

Adagio's Round Trip

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Adagio Therapeutics, Inc. Announces Executive Changes

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Adagio Therapeutics, Inc. Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Adagio Therapeutics, Inc. Reports Updates on Its Lead Covid-19 Antibody Program, ADG20

Adagio Therapeutics, Inc. Announces the Independent Data Monitoring Committee (IDMC) for the EVADE Phase 2/3 Trial of ADG20 for the Prevention of COVID-19

Adagio Therapeutics, Inc. has completed an IPO in the amount of $309.4 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members